

# LoPAG Platelets in London

Rachel Moss  
May 2013



London Platelet Action Group



Platelets in London are  
harder to get than a table at  
The Ivy!

# In the beginning we had graphs and the Blood Stocks Management Scheme data






## Moving Annual Total of Platelet Issues to Hospitals - 000s


Platelet issues from NHSBT March 2001 - July 2012

28% increase in  
platelet issues

Greatest change over 5 years  
(‘07-‘12) and still rising



## Platelets RTC



## RTC Quarterly Hospital RBC/PLT Issue Report

page No 3

### London RTC

### Regional Blood Group Distribution Data \*\*

O Pos	O Neg	A Pos	A Neg	B Pos	B Neg	AB Pos	AB Neg
39.0%	5.9%	30.5%	5.1%	13.5%	1.6%	3.9%	0.5%

### Issues from NHSBT for :- 2012/13 Q3

Hospital Details	Red Cell Issues from NHSBT Centres										RBC Stock Move	Issues	PLT Stock Move
Hospital Name	O Pos	O Neg	A Pos	A Neg	B Pos	B Neg	AB Pos	AB Neg	All RBC's	% O Neg	Corrected Total	All PLT's	Corrected Total
HCA Laboratories	857	191	494	93	169	62	54	26	1,946	9.8%		492	
St. George's Hospital	1,920	488	1,492	270	479	181	115	34	4,979	9.8%		817	
Royal Marsden Hospital, Fulham Road	597	142	358	145	125	66	28	20	1,481	9.6%		324	
Newham University Hospital	396	108	239	91	205	65	33	0	1,137	9.5%		81	
Queen's Hospital (Romford)	965	298	1,093	312	326	92	62	32	3,180	9.4%		469	
Charing Cross Hospital	434	134	419	105	226	38	62	41	1,459	9.2%		134	
Ealing General Hospital	505	131	384	73	261	55	6	14	1,429	9.2%		70	
Princess Royal University Hospital,(Farnborough)	654	149	574	106	70	39	42	0	1,634	9.1%		189	
Kingston Hospital	914	202	794	133	78	33	39	25	2,218	9.1%		283	
King George Hospital	373	99	362	74	109	36	28	12	1,093	9.1%		53	
St. Bartholomew's Hospital	687	176	624	178	238	69	89	0	2,061	8.5%		1,142	
Chase Farm Hospital	412	105	369	82	126	38	40	59	1,231	8.5%		74	
Hammersmith Hospital	1,882	414	1,360	305	705	121	105	46	4,938	8.4%		1,157	
The London Clinic	358	87	323	88	134	34	49	16	1,089	8.0%		390	

Data supplied by Blood Stocks Management Scheme



# Platelet Issues by Usage Category

## Platelet Usage - Very High

Monthly Issues last 12 months



(Apr 2011 to Mar 2012)

Average Monthly Issues




## Summary of Platelet Issues in London

Month	Group A total	Total Issues	% Group A Issues
Apr-12	2,926	5,649	51.8%
May-12	3,308	6,296	52.5%
Jun-12	2,653	5,381	49.3%
Jul-12	3,110	6,246	49.8%
Aug-12	3,305	6,234	53.0%
Sep-12	2,946	5,688	51.8%
Oct-12	3,222	6,134	52.5%
Nov-12	3,304	6,418	51.5%
Dec-12	3,237	6,225	52.0%
Jan-13	3,114	6,270	49.7%
Feb-13	2,848	5,426	52.5%
Mar-13	3,128	5,973	52.4%
<b>Total:</b>	<b>37,101</b>	<b>71,940</b>	
<b>Average:</b>		<b>5,995</b>	<b>51.6%</b>





● ● ● | LoPAG had arrived



# LoPAG Proposal

- That all hospitals look at local laboratory and clinical practices that could help to reduce platelet usage by 10%
- If London RTC hospitals achieved this it would improve NHSBT stocks and hence availability
- It would have a huge impact nationally because London RTC hospitals use more than any other RTC
- Every hospital nominate a platelet champion to take the initiative forward



# LoPAG Plan

- Email every RTC member and ask for a Platelet Champion from their transfusion team
- Set out 10 Top Tips
- Offer BSMS VANESA training if wanted
- The platelet champion would link in with LoPAG
- LoPAG hoped to learn of more good practice ideas to be shared amongst champions
- LoPAG to offer support and resources for transfusion teams if needed



## London Platelet Action Group

### Top Tips to reduce platelet usage and wastage

1.	<b>Should your hospital stock platelets?</b> <i>The BSMS has produced a tool which may help you decide if that is appropriate or not.</i> <a href="http://www.bloodstocks.co.uk/pdf/PlateletStockholdingAlgorithm.pdf">http://www.bloodstocks.co.uk/pdf/PlateletStockholdingAlgorithm.pdf</a>
2.	<b>Could your hospital share platelets with another local hospital?</b> <i>Some smaller hospitals successfully share with larger hospitals and some Trusts rotate platelet stocks between their hospitals to reduce wastage.</i>
3.	<b>Could your hospital introduce a locally defined and agreed dereservation period for platelets allocated to a named patient?</b> <i>Hospitals where platelets are ordered to cover specific transfusion events have successfully altered clinical practice so platelets are returned to stock after a short period (4-12 hours) if they have not been transfused.</i>
4.	<b>Consider swapping long-dated platelets for short-dated ones</b> <i>If you know a patient is going to be transfused, give them the shortest dated platelets.</i>
5.	<b>Consider using different ABO group platelets in adults who are <u>bleeding</u></b> <i>Although when used prophylactically ABO matched platelets survive longer, in the bleeding patient a different ABO group will be just as effective at stopping the bleeding.</i>
6.	<b>Consider using RhD positive platelets in adult males who are <u>bleeding</u></b> <i>Give RhD negative platelets for RhD negative patients where anti-D would be a problem but in adult males who are actively bleeding, use RhD positive platelets if you have them available</i>
7.	<b>Introduce the National Blood Transfusion Committee Indication Codes for platelets so that any requests outside the accepted criteria can be reviewed if appropriate</b> <i>This could be done to empower the BMS staff or used as a way of deciding when to get the haematology medical staff to intervene.</i>
8.	<b>Double-dose platelets are not necessary in most prophylactic situations – ‘why use two when one will do?’</b> <i>The PLADO clinical trial (N Engl J Med 2010; 362:600-613) has shown that standard dose prophylactic platelets are just as effective as high dose prophylactic platelets.</i>
9.	<b>Review the timeliness of platelet counts or other tests used to inform the decision to prescribe platelets.</b> <i>Often platelet orders are made in anticipation of a low platelet count and sometimes platelets are transfused before the count is available. Where possible use of point of care testing and rapid turnaround of laboratory tests to support active clinical decision making.</i>
10.	<b>Work at it – share practice with colleagues in other hospitals – and celebrate success!</b>



# 10 Top Tips

1. Should your hospital stock platelets?
2. Could your hospital share platelets with another local hospital?
3. Could your hospital introduce a locally defined and agreed dereservation period for platelets allocated to a named patient?
4. Consider swapping long-dated platelets for short-dated ones
5. Consider using different ABO group platelets in adults who are bleeding



# 10 Top Tips

6. Consider using RhD positive platelets in adult males who are bleeding
7. Introduce the National Blood Transfusion Committee Indication Codes for platelets so that any requests outside the accepted criteria can be reviewed if appropriate
8. Double-dose platelets are not indicated in most situations – ‘why use two when one will do?’
9. Review the timeliness of platelet counts or other tests used to inform the decision to prescribe platelets.
10. Work at it – share practice with colleagues in other hospitals – and celebrate success!






# LoPAG Survey




- 6 months after Top Ten Tips sent out
- Survey sent to Platelet Champions
- Main premise asking if they do any of the suggested tips and if so how/why
- Results fed back to champions at Platelet Champions Day


Does your hospital  
hold “stock” platelets?



Do you share  
platelets with other  
local hospitals?



Do you have a  
defined dereservation  
period for platelets  
allocated to a named  
patient?



Do you have a defined dereservation period for platelets allocated to a named patient?

De-reservation period	
4 hours	2
12 hours	1
24 hours	3
48 hours	3
24-48 hours	1



# Champions Day – Nov 2012

09:30-10:00	Registration & coffee	All
<b>10:00 – 12:30: the classroom sessions</b>		
10:00 – 10:05	Welcome and introduction	Rachel Moss LoPAG Chair
10:05 – 10:45	Back to basics – what does a platelet actually do?	Andy Miller Senior Scientific Officer NHSBT
10:35 – 11:15	Platelets – it's the special treatment needed	Delordson Kallon NHSBT
11:15 - 11:45	TEG and Platelet mapping – how it works and how it reduces use	Oliver Pearson, Product Specialist , Haemonetics
11:45 - 12:30	LoPAG Survey results – what did we learn?	Carol Cantwell and LoPAG Steering group
12:30 – 13:30	Lunch	All
<b>13:30 – 16:00: the interactive sessions</b>		
13:30 – 14:30	Platelet Training Packs – developing a pack to take back to base	Workshop
14:30: 14:45	Comfort break	All
14:45 – 15:45	Indication Codes – do we use them and what do they bring to the decision to transfuse?	Workshop



# Platelet Champions Tool Kit



# Back to basics – what does a platelet actually do?

- Uploaded to You Tube
- Title = **Platelets the basics**: given by Andy Miller London RTC


<http://www.youtube.com/watch?v=PXj5Imd8avs>



### Algorithm to aid hospital decision making for holding stock platelets

The number of hospitals routinely holding a stock of platelets has increased from 10% in 2003 to 22% in 2009 (from 23 hospitals to 51 hospitals). There is anecdotal evidence that the number of hospitals holding stocks of platelets continues to increase.

The objective of the algorithm is to aid hospital decision making for holding platelet stock and has been collated using output from hospital participants at the BSMS regional meetings which took place in May 2011.



# Indication Codes for Transfusion- An Audit Tool

The indications for transfusion provided below are taken from UK national guidelines for the use of blood components. Each indication has been assigned a number, which may be used by clinicians when requesting blood or for documentation purposes. Specific details regarding the patient's diagnosis and any relevant procedures to be undertaken should also be provided. These are current guidelines and may change depending on new evidence.

■ recently updated indication codes

## Red cell concentrates

### R1. Acute blood loss

In patients with massive haemorrhage, the haemoglobin concentration (Hb) is a poor indicator of acute blood loss and empirical decisions about the immediate use of red cell transfusion are required by clinicians experienced in resuscitation. The following is a guide to the likelihood of the need for blood transfusion, although estimation of blood losses may be difficult:-

- <30% loss of blood volume (< 1500ml in an adult): transfuse crystalloids. Red cell transfusion is unlikely to be necessary.
- 30-40% loss of blood volume (1500-2000ml in an adult): rapid volume replacement is required with crystalloids. Red cell transfusion will probably be required to maintain recommended Hb levels.
- >40% loss of blood volume (>2000ml in an adult): rapid volume replacement including red cell transfusion is required.

When normovolaemia has been achieved/maintained, frequent measurement of Hb (for example, by near patient testing) can be used to guide the use of red cell transfusion. Where future blood loss is unpredictable (e.g. gastrointestinal haemorrhage), a Hb threshold of 10g/dl to guide transfusion is recommended; otherwise the objective is to maintain circulating blood volume and Hb >7 g/dl in otherwise fit patients, and >8g/dl in elderly patients and those with known cardiovascular disease.

### Peri-operative transfusion

Many patients undergoing elective surgical operations will not require transfusion support if their Hb is normal before surgery. Assuming normovolaemia has been maintained, the Hb can be used to guide the use of red cell transfusion.

### R2. Hb < 7g/dl.

### R3. Hb < 8 g/dl in a patient with known cardiovascular disease, or those with significant risk factors for cardiovascular disease (e.g. elderly patients, and those with hypertension, diabetes mellitus, peripheral vascular disease).

### Critical Care

### R4. Transfuse to maintain the Hb >7g/dl, and >8g/dl in elderly patients and those with known cardiovascular disease.

### Post-chemotherapy

### R5. There is no evidence-base to guide practice. Most hospitals use a transfusion threshold of a Hb of 8 or 9g/dl.

### Radiotherapy

### R6. There is little evidence-base to guide practice. Suggest transfuse to maintain the Hb >10g/dl.


### Chronic anaemia

### R7. Transfuse to maintain the haemoglobin concentration to prevent symptoms of anaemia. Many patients with chronic anaemia may be asymptomatic with a Hb >8g/dl.

## Fresh frozen plasma

(Dose - 12-15 ml/kg body weight equivalent to 4 units for an adult)

- F1. Replacement of single coagulation factor deficiencies, where a specific or combined factor concentrate is unavailable e.g. factor V.
- F2. Immediate reversal of warfarin effect, in the presence of life-threatening bleeding. FFP only has a partial effect and is not the optimal treatment; prothrombin complex concentrates are preferred.



- F3. Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and abnormal coagulation results.
- F4. Thrombotic thrombocytopenic purpura (TTP), usually in conjunction with plasma exchange.
- F5. Massive transfusion; local protocols for serious bleeding should be followed and may recommend empirical use of FFP and a specific ratio of FFP to red cells.
- F6. Liver disease; patients with a PT within 4 seconds of the control value are unlikely to benefit from the use of FFP.

## Cryoprecipitate

(Dose - 2 pooled packs, equivalent to 10 single units, for an adult).

Cryoprecipitate should be used in combination with FFP unless there is an isolated deficiency of fibrinogen.

- C1. Acute disseminated intravascular coagulation (DIC), where there is bleeding and a fibrinogen level <1g/l.
- C2. Advanced liver disease, to correct bleeding or as prophylaxis before surgery, when the fibrinogen level <1g/l.
- C3. Bleeding associated with thrombolytic therapy causing hypofibrinogenaemia.
- C4. Hypofibrinogenaemia (fibrinogen level <1g/l) secondary to massive transfusion.
- C5. Renal failure or liver failure associated with abnormal bleeding where DDAVP is contraindicated or ineffective.
- C6. Inherited hypofibrinogenaemia, where fibrinogen concentrate is not readily available.



## Platelet concentrates

(Dose - 15 ml/kg body weight for children <20kg; 1 adult therapeutic dose for adults and older children)

### Bone marrow failure

- P1. To prevent spontaneous bleeding when the platelet count <10 x 10<sup>9</sup>/l.
- P2. To prevent spontaneous bleeding when the platelet count <20 x 10<sup>9</sup>/l in the presence of additional risk factors for bleeding such as sepsis or haemostatic abnormalities.
- P3. To prevent bleeding associated with invasive procedures. The platelet count should be raised to >50 x 10<sup>9</sup>/l before lumbar puncture, epidural anaesthesia, insertion of intravascular lines, transbronchial and liver biopsy, and laparotomy, and to >100 x 10<sup>9</sup>/l before surgery in critical sites such as the brain or the eyes.

### Critical care/surgery

### P4. Massive blood transfusion. The platelet count can be anticipated to be <50 x 10<sup>9</sup>/l after 2 x blood volume replacement. Aim to maintain platelet count >75 x 10<sup>9</sup>/l, which allows a margin of safety to ensure platelet count >50 x 10<sup>9</sup>/l. Keep the platelet count >100 x 10<sup>9</sup>/l if multiple, eye or CNS trauma.

- P5. Bleeding, not surgically correctable, and with associated acquired platelet dysfunction e.g. post-cardiopulmonary bypass, possibly combined with the use of potent anti-platelet agents such as clopidogrel.
- P6. Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and severe thrombocytopenia.
- P7. Inherited platelet dysfunction disorders e.g. Glanzmanns thrombasthenia with bleeding or as prophylaxis before surgery.

### Immune thrombocytopenia

- P8. Autoimmune thrombocytopenia, in the presence of major haemorrhage.
- P9. Post-transfusion purpura, in the presence of major haemorrhage.
- P10. Neonatal alloimmune thrombocytopenia, to treat bleeding or as prophylaxis to maintain the platelet count >50 x 10<sup>9</sup>/l.



## References

Association of Anaesthetists of Great Britain and Ireland (2008). Blood transfusion and the anaesthetist: red cell transfusion (www.aagbi.org).  
British Committee for Standards in Haematology (2001). Guidelines for the clinical use of red cell transfusion. *British Journal of Haematology*, 113, 24-31.  
British Committee for Standards in Haematology (2006). Guidelines on the management of massive blood loss. *British Journal of Haematology*, 135, 634-641.  
British Society of Gastroenterology (2002). Non-variceal upper gastrointestinal haemorrhage: guidelines. *Gut*, 51 (suppl IV), iv-iv6.

Scottish Intercollegiate Guidelines Network (2001). Perioperative blood transfusion for elective surgery (www.sign.ac.uk).  
Scottish Intercollegiate Guidelines Network (2008). Management of upper and lower gastrointestinal bleeding (www.sign.ac.uk).  
British Committee for Standards in Haematology (2003). Guidelines for the use of platelet transfusions. *British Journal of Haematology*, 122, 10-23.  
British Committee for Standards in Haematology (2004). Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. *British Journal of Haematology*, 126, 11-28.  
Scherer A et al for the European Society of Clinical Oncology (2001). Platelet transfusion for patients with cancer: clinical practice guidelines. *Journal of Clinical Oncology*, 19, 1519-1538.

# Platelet App

## Prescribing Platelets?

**NHS**  
**Blood and Transplant**

### The New Platelet Transfusion Mobile Site

Is designed to give quick easy access to the national guidelines on platelet transfusion and is specifically designed for smartphones and tablets so you have access wherever you need it.

This site works like an app and allows clinicians to check platelet guidelines and thresholds for transfusion at the bedside.

#### Features Include:

- Platelet transfusion thresholds prior to common procedures
- Reasons why prophylactic threshold can be increased
- Contraindications to platelet transfusions
- A paediatric dose calculator.



Your feedback is welcome - email: [NHSBT.CustomerService@nhsbt.nhs.uk](mailto:NHSBT.CustomerService@nhsbt.nhs.uk)





# Double Dose Platelets

**NHS**  
*Blood and Transplant*

**Platelets**  
**Don't use two...**



**...when one will do**

For prophylactic use in a 70kg adult, one adult therapeutic dose (ATD) typically gives an immediate rise in platelet count of

**approximately 20 - 40 x 10<sup>9</sup>/l<sup>(1)</sup>**

Do not administer double dose platelets for prophylactic transfusions as this practice does not decrease the risk of bleeding.<sup>(2)</sup>

Request and administer one unit/ATD, then reassess your patient.

A platelet increment can be obtained 10 minutes after completion of the transfusion.<sup>(3)</sup>

1. McClelland DBL Ed (2006) Handbook of Transfusion Medicine 4th Edition, The Stationery Office

2. Slichter SL, Kaufman RM, Azmann SE, et al. Dose of prophylactic platelet transfusions and prevention of haemorrhage. *N Engl J Med* 2010;362:600-13.

3. O'Connell E, Lee EJ, Schiffer CA. The value of 10-minute post transfusion platelet counts. *Transfusion* 1988; 28: 66-67.


Further copies available from [NHSBT.CustomerService@nhsbt.nhs.uk](mailto:NHSBT.CustomerService@nhsbt.nhs.uk) December 2011 V1

1112 496



London Platelet Action Group

# Manchester Platelet Decision Chart



Thanks to Dr Kate Pendry & team

## NEONATES AND CHILDREN

Keep Platelets above

### ROUTINE PROPHYLAXIS FOR NEONATES

- STABLE PRE-TERM TERM INFANT
- SICK PRE-TERM / TERM INFANT
- NAIT (NEONATAL ALLOIMMUNE THROMBOCYTOPENIA)

>20  
>30  
>30

### PROPHYLACTIC USE FOR CHILDREN WITH RISK FACTORS

- SEVERE MUCOSITIS, LOCAL TUMOUR INFILTRATION
- PLATELET COUNT LIKELY TO FALL TO < 10, ANTICOAGULATION THERAPY
- SEVERE HYPERLEUCOCYTOSIS OR DIC WITH INDUCTION THERAPY
- DIC (DISSEMINATED INTRAVASCULAR COAGULATION)

>20  
>40  
>20

### PROPHYLACTIC PROCEDURE

- ECMO
- LUMBAR PUNCTURE

>100  
>40

## ADULTS

Keep Platelets above

### CHRONIC BONE MARROW FAILURE

NOT INDICATED

### REVERSIBLE BONE MARROW

>10

### INVASIVE PROCEDURES

- LP / CVL INSERTION / TRANSBRONCHIAL / LIVER BIOPSY / LAPAROTOMY
- EPIDURAL
- EYE / CNS SURGERY

>50  
>80  
>100

### MASSIVE TRANSFUSION

- NO COMPLICATION
- WITH HEAD INJURY / COMPLEX TRAUMA

>75  
>100


### DIC

- WITH BLEEDING

>75

### PLATELET DISORDER

- INHERITED
- ANTI-PLATELET AGENTS (ASPIRIN / CLOPIDOGREL),
- CARDIOPULMONARY BYPASS, OTHER ACQUIRED PLATELET DEFECT





# LoPAG

## Achieved


- Working group of RTC
- Top 10 tips
- Resources available
- Top 10 tips survey results
- Champions Day
- Talk on You Tube
- LoPAG talks – TP day, SNBTS
- HoT SIG May 2013

## Future Plans

- Platelet education pack
- Summer Champions newsletter
- LoPAG Day for SpRs
- Repeat Champions Survey and day 2014







## Acknowledgements

- LoPAG members
- Dr Kate Pendry
- Andy Miller
- BSMS Steering Group
- Platelet Champions



London Platelet Action Group